Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing
Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.
Pharma & Biotech
Pharma & Biotech
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
Pharma & Biotech
Why Gilead Sciences’ Arcellx acquisition reshapes the competitive dynamics of BCMA CAR T therapy
Gilead Sciences’ acquisition of Arcellx signals a strategic shift in CAR T therapy control and scale. Find out what it changes for multiple myeloma.
Pharma & Biotech
FDA removes CNS limitation for Yescarta, reshaping the regulatory boundary for CAR T therapy in primary CNS lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration to update the prescribing information for Yescarta axicabtagene ciloleucel by removing the prior limitation of use in patients with relapsed or refractory primary central nervous system lymphoma. The decision follows safety findings from an investigator sponsored Phase 1
Pharma & Biotech
Gilead Sciences acquires RP-3467 from Repare Therapeutics in $30m synthetic lethality deal
Gilead Sciences acquires Repare’s RP-3467 Polθ inhibitor for up to $30M. Find out what this means for BRCA-targeted therapy and synthetic lethality M&A.
Pharma & Biotech
What Arcus Biosciences’ STAR-221 failure reveals about TIGIT fatigue in immunotherapy
Arcus Biosciences, Inc. has terminated its global Phase 3 STAR-221 study evaluating domvanalimab, an investigational anti-TIGIT antibody, in combination with zimberelimab and chemotherapy for advanced upper gastrointestinal cancers. The discontinuation, announced in partnership with Gilead Sciences, Inc., followed a pre-specified interim overall survival analysis that found no benefit compared to the nivolumab-based control arm. Arcus